(Post-pandemic Era)-Global Toxoid Vaccine Market (Sales, Revenue, Price, Gross Profit and Competitors Analysis of Major Market) from 2015-2026

  • Report Code : 454758
  • Pages : 106
  • Published On : Oct 2020
  • Industry : Medical Devices
  • Format :

Choose License Type

Single User License: US$ 3,650
Multi User License: US$ 0
Corporate User License: US$ 5,600
Summary

As the world continues to deal with COVID-19, economies are moving into recession, under multiple adverse factors, the GDP of European and American countries in the second quarter suffered a historical contraction. At an annualized rate, the US GDP fell by 32.9% month on month, while the overall GDP of the euro zone fell by 12.1%.

Moreover, the economic prospects of Europe and the United States in the third quarter under the epidemic situation are hardly optimistic. The resumption of work and production not only brought economic data back, but also triggered a rebound in the epidemic situation. At present, the United States is still the 'epicenter' of the global epidemic. The total number of confirmed cases has exceeded 4.8 million, and the epidemic situation in some European countries has also rebounded. Affected by this, more than 20 states in the United States have announced the suspension or withdrawal of part of the economic restart plan. Britain and Italy have also decided to extend the state of emergency. The rebound of the epidemic situation has posed considerable risks to the economic prospects of Europe and the United States.
In the second quarter of this year, US GDP shrank by 9.5% on a month on month basis, or 32.9% at an annual rate, the largest decline since the 1940s. Data show that the sharp decline in personal consumption is the main drag on the U.S. GDP growth in the second quarter.
Compared with the United States, Europe's economic contraction in the second quarter was smaller, but it was also the lowest on record, with Germany and France contracting more than 10%. According to the data released by the Federal Bureau of statistics, Germany's GDP fell by 10.1% in the second quarter after adjusting for prices, seasons and working days, the largest decline since the quarterly economic data were available in 1970.
Thanks to the effective control and policy support of the new epidemic, China's economy rebounded sharply in the second quarter. The growth rate of manufacturing industry, which accounted for about 28% of GDP, rebounded sharply to 4.4% from the negative value in the first quarter. Chinese original equipment manufacturers (OEMs) and suppliers are ramping up production. And there are increased investments in digital footprints in manufacturing. OEMs in other parts of the world are offering incentives to drive sales. XYZResearch published a report for global Toxoid Vaccine market in this environment.

In terms of revenue, this research report indicated that the global Toxoid Vaccine market was valued at USD XXX million in 2019, and it is expected to reach a value of USD XXX million by 2026, at a CAGR of XX % over the forecast period 2021-2026. Correspondingly, the forecast analysis of Toxoid Vaccine industry comprises of China, USA, Japan, India, Korea and South America, with the production and revenue data in each of the sub-segments.

The Sanofi aims at producing XX Toxoid Vaccine in 2020, with XX % production to take place in global market, Merck accounts for a volume share of XX %.

Regional Segmentation (Value; Revenue, USD Million, 2015 - 2026) of Toxoid Vaccine Market by XYZResearch Include
China
EU
USA
Japan
India
Southeast Asia
South America
Competitive Analysis; Who are the Major Players in Toxoid Vaccine Market?
Sanofi
Merck
Pfizer
Bayer
Virbac
GSK
Ceva Corporate
...
Major Type of Toxoid Vaccine Covered in XYZResearch report:
Human Beings
Animal
Application Segments Covered in XYZResearch Market
Hospital
Clinics
Public Services
Others

For any other requirements, please feel free to contact us and we will provide you customized report.

Table of Contents Global Toxoid Vaccine Market Analysis 2020, With Top Companies, Production, Revenue, Consumption, Price and Growth Rate 1 Market Scope 1.1 Product Details and Introduction 1.1.1 Human Beings -Product Introduction and Major Manufacturers 1.1.2 Animal -Product Introduction and Major Manufacturers 1.2 Market Snapshot 1.2.1 Major Companies Overview 1.2.2 Market Concentration 1.2.3 Six-Year Compound Annual Growth Rate (CAGR) 2 Global Toxoid Vaccine Market Assessment, by Segmentation 2.1 Type Breakdown Estimates & Forecast, Sales Volume (2015-2026) 2.2 Type Breakdown Estimates & Forecast, Sales Value (2015-2026) 2.3 Application Breakdown Estimates & Forecast, by Application (2015-2026) 3 Regional Market Analysis 3.1 China Toxoid Vaccine Market 3.1.1 Top Companies leading Toxoid Vaccine Development in China (2015-2020) 3.1.2 Sales Value of Major Company in China Market (2015-2020) 3.1.3 China Toxoid Vaccine Price (USD/Unit), by Type (2019-2020) 3.1.4 Sales in China Market, by Type (2015-2026) 3.2 EU Toxoid Vaccine Market 3.2.1 Top Companies leading Toxoid Vaccine Development in EU (2015-2020) 3.2.2 Sales Value of Major Company in EU Market (2015-2020) 3.2.3 EU Toxoid Vaccine Price (USD/Unit), by Type (2019-2020) 3.2.4 Sales in EU Market, by Type (2015-2026) 3.3 USA Toxoid Vaccine Market 3.3.1 Top Companies leading Toxoid Vaccine Development in USA (2015-2020) 3.3.2 Sales Value of Major Company in USA Market (2015-2020) 3.3.3 USA Toxoid Vaccine Price (USD/Unit), by Type (2019-2020) 3.3.4 Sales in USA Market, by Type (2015-2026) 3.4 Japan Toxoid Vaccine Market 3.4.1 Top Companies leading Toxoid Vaccine Development in Japan (2015-2020) 3.4.2 Sales Value of Major Company in Japan Market (2015-2020) 3.4.3 Japan Toxoid Vaccine Price (USD/Unit), by Type (2019-2020) 3.4.4 Sales in Japan Market, by Type (2015-2026) 3.5 India Toxoid Vaccine Market 3.5.1 Top Companies leading Toxoid Vaccine Development in India (2015-2020) 3.5.2 Sales Value of Major Company in India Market (2015-2020) 3.5.3 India Toxoid Vaccine Price (USD/Unit), by Type (2019-2020) 3.5.4 Sales in India Market, by Type (2015-2026) 3.6 Southeast Asia Toxoid Vaccine Market 3.6.1 Top Companies leading Toxoid Vaccine Development in Southeast Asia (2015-2020) 3.6.2 Sales Value of Major Company in Southeast Asia Market (2015-2020) 3.6.3 Southeast Asia Toxoid Vaccine Price (USD/Unit), by Type (2019-2020) 3.6.4 Sales in Southeast Asia Market, by Type (2015-2026) 3.7 South America Toxoid Vaccine Market 3.7.1 Top Companies leading Toxoid Vaccine Development in South America (2015-2020) 3.7.2 Sales Value of Major Company in South America Market (2015-2020) 3.7.3 South America Toxoid Vaccine Price (USD/Unit), by Type (2019-2020) 3.7.4 Sales in South America Market, by Type (2015-2026) 4 Value Chain (Impact of COVID-19) 4.1 Toxoid Vaccine Value Chain Analysis 4.1.1 Upstream 4.1.2 Downstream 4.2 COVID-19 Impact on Toxoid Vaccine Industry 4.2.1 Industrial Policy Issued Under the Epidemic Situation 4.3 Cost-Under the Epidemic Situation 4.3.1 Cost of Raw Material 4.4 Channel Analysis 4.4.1 Distribution Channel-Under the Epidemic Situation 4.4.2 Distributors 5 Regional Market Forecast (2021-2026) 5.1 Global Toxoid Vaccine Sales and Growth Rate (2021-2026) 5.2 Global Toxoid Vaccine Sales Value and Growth Rate (2021-2026) 6 Toxoid Vaccine Competitive Analysis 6.1 Sanofi 6.1.1 Sanofi Company Profiles 6.1.2 Sanofi Product Introduction 6.1.3 Sanofi Toxoid Vaccine Production, Revenue (2015-2020) 6.1.4 SWOT Analysis 6.2 Merck 6.2.1 Merck Company Profiles 6.2.2 Merck Product Introduction 6.2.3 Merck Toxoid Vaccine Production, Revenue (2015-2020) 6.2.4 SWOT Analysis 6.3 Pfizer 6.3.1 Pfizer Company Profiles 6.3.2 Pfizer Product Introduction 6.3.3 Pfizer Toxoid Vaccine Production, Revenue (2015-2020) 6.3.4 SWOT Analysis 6.4 Bayer 6.4.1 Bayer Company Profiles 6.4.2 Bayer Product Introduction 6.4.3 Bayer Toxoid Vaccine Production, Revenue (2015-2020) 6.4.4 SWOT Analysis 6.5 Virbac 6.5.1 Virbac Company Profiles 6.5.2 Virbac Product Introduction 6.5.3 Virbac Toxoid Vaccine Production, Revenue (2015-2020) 6.5.4 SWOT Analysis 6.6 GSK 6.6.1 GSK Company Profiles 6.6.2 GSK Product Introduction 6.6.3 GSK Toxoid Vaccine Production, Revenue (2015-2020) 6.6.4 SWOT Analysis 6.7 Ceva Corporate 6.7.1 Ceva Corporate Company Profiles 6.7.2 Ceva Corporate Product Introduction 6.7.3 Ceva Corporate Toxoid Vaccine Production, Revenue (2015-2020) 6.7.4 SWOT Analysis 7 Conclusion

Global Cold Chain Equipment Market (2024 Edition): Analysis By Equipment Type (Refrigerators, Deep Freezers & Reefer Containers, Cold Boxes & Vaccine Carriers, Cold Rooms/ Chillers, Other Equipment Types), By Purpose, By End-use, By Region, By Country: Market Insights and Forecast (2020-2030)...

Executive Summary Azoth Analytics has released a research report titled "Global Cold Chain Equipment Market (2024 Edition)" which provides a complete analysis of the Global Cold Chain Equipment market in terms of market segmentation By Equipment Type (Refrigerators, Deep Freezers & Reef...

Global Vaccine Supply Chain Solutions Market Size, Key Players, Research Insights, Emerging Opportunities, COVID-19 Impact and Emerging Trends By 2030...

Overview of the Global Vaccine Supply Chain Solutions Market: The report discusses everything a marketer requires before investing in the global Vaccine Supply Chain Solutions Market during the forecast period 2023-...

Global Digital Vaccine Tracking System Market Size, Key Players, Research Insights, Emerging Opportunities, COVID-19 Impact and Emerging Trends By 2030...

Overview of the Global Digital Vaccine Tracking System Market: The report discusses everything a marketer requires before investing in the global Digital Vaccine Tracking System Market during the forecast period 202...

Asia Pacific Preventive Vaccines Market 2022-2032 by Vaccine Type, Disease, Administration, Patient, and Country: Trend Forecast and Growth Opportunity...

Asia Pacific preventive vaccines market will grow by 7.9% annually with a total addressable market cap of $217.46 billion over 2023-2032, driven by the rising prevalence of several infectious diseases, rising R&D investment and technological advancement in vaccination technologies, rising need for p...

Europe Preventive Vaccines Market 2022-2032 by Vaccine Type, Disease, Administration, Patient, and Country: Trend Forecast and Growth Opportunity...

Europe preventive vaccines market was valued at $18.02 billion in 2022 and will grow by 5.1% annually over 2022-2032, driven by the rising prevalence of several infectious diseases, rising R&D investment and technological advancement in vaccination technologies, rising need for preventive vaccines s...

North America Preventive Vaccines Market 2022-2032 by Vaccine Type, Disease, Administration, Patient, and Country: Trend Forecast and Growth Opportunity...

North America preventive vaccines market is projected to grow by 6.3% annually in the forecast period and reach $46.90 billion by 2032, driven by the rising prevalence of several infectious diseases, rising R&D investment and technological advancement in vaccination technologies, rising need for pre...

Global Preventive Vaccines Market 2022-2032 by Vaccine Type, Disease, Administration, Patient, and Region: Trend Forecast and Growth Opportunity...

Global preventive vaccines market will reach $120.07 billion by 2032, growing by 6.4% annually over 2022-2032, driven by the rising prevalence of several infectious diseases, rising R&D investment and technological advancement in vaccination technologies, rising need for preventive vaccines such as ...

2023-2028 Global and Regional Whole Cell Cholera Vaccine Industry Status and Prospects Professional Market Research Report Standard Version...

The global Whole Cell Cholera Vaccine market is expected to reach US$ XX Million by 2028, with a CAGR of XX% from 2023 to 2028, based on HNY Research newly published report. The prime objective of this report is to provide the insights on the post COVID-19 impact which will help market players i...

2023-2028 Global and Regional Viral Vaccine Media Industry Status and Prospects Professional Market Research Report Standard Version...

The global Viral Vaccine Media market is expected to reach US$ XX Million by 2028, with a CAGR of XX% from 2023 to 2028, based on HNY Research newly published report. The prime objective of this report is to provide the insights on the post COVID-19 impact which will help market players in this ...

2023-2028 Global and Regional Vero Cell Rabies Vaccine Industry Status and Prospects Professional Market Research Report Standard Version...

The global Vero Cell Rabies Vaccine market is expected to reach US$ XX Million by 2028, with a CAGR of XX% from 2023 to 2028, based on HNY Research newly published report. The prime objective of this report is to provide the insights on the post COVID-19 impact which will help market players in ...